GA
LABU icon

Gateway Advisory’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Gateway Advisory’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,000
Closed -$366K – 137
2023
Q4 		$366K Buy
+3,000
New +$230K 0.07% 82

Other funds holding LABU

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
TI
Tidal Investments Milwaukee, Wisconsin $47.4B AUM 59.58% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Gateway Advisory's LABU Position: Q1 2024 in Review

Gateway Advisory sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2024, closing a stake of 3,000 shares — an estimated $366K sold.

Gateway Advisory first reported a position in LABU in Q4 2023 and held it in 1 quarter. The position peaked at $366K in Q4 2023. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2024.

  • Gateway Advisory reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2024 after selling out during the quarter.
  • Gateway Advisory sold 3,000 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2024, an estimated $366K.
  • Gateway Advisory first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2023 and held it in 1 quarter.
  • Gateway Advisory's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $366K in Q4 2023.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2024.

Based on Gateway Advisory's 13F filing for Q1 2024, filed 15 May 2024.